ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 58 filers reported holding ADC THERAPEUTICS SA in Q4 2021. The put-call ratio across all filers is 0.58 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,297 | -15.4% | 22,629 | +102.7% | 0.00% | – |
| Q2 2023 | $24,002 | +29.8% | 11,164 | +17.7% | 0.00% | – |
| Q1 2023 | $18,490 | -26.0% | 9,482 | +44.0% | 0.00% | – |
| Q4 2022 | $25,000 | 0.0% | 6,584 | +25.2% | 0.00% | – |
| Q3 2022 | $25,000 | -43.2% | 5,257 | -4.1% | 0.00% | – |
| Q2 2022 | $44,000 | -6.4% | 5,483 | +68.8% | 0.00% | – |
| Q1 2022 | $47,000 | +840.0% | 3,248 | +1270.5% | 0.00% | – |
| Q4 2021 | $5,000 | -44.4% | 237 | -30.7% | 0.00% | – |
| Q3 2021 | $9,000 | 0.0% | 342 | -12.8% | 0.00% | – |
| Q2 2021 | $9,000 | +80.0% | 392 | +116.6% | 0.00% | – |
| Q1 2021 | $5,000 | -16.7% | 181 | 0.0% | 0.00% | – |
| Q4 2020 | $6,000 | +20.0% | 181 | +9.7% | 0.00% | – |
| Q3 2020 | $5,000 | -37.5% | 165 | -7.8% | 0.00% | – |
| Q2 2020 | $8,000 | – | 179 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 5,402,041 | $4,845,631 | 1.54% |
| Sio Capital Management, LLC | 3,294,534 | $2,955,197 | 0.92% |
| Redmile Group, LLC | 14,178,045 | $12,717,706 | 0.60% |
| AlphaCentric Advisors LLC | 1,068,468 | $958,416 | 0.54% |
| Vantage Consulting Group Inc | 850,737 | $763,111 | 0.51% |
| Blue Owl Capital Holdings LP | 733,568 | $654,489 | 0.51% |
| Affinity Asset Advisors, LLC | 1,100,000 | $986,700 | 0.28% |
| Frazier Life Sciences Management, L.P. | 1,647,030 | $1,477,386 | 0.10% |
| Indie Asset Partners, LLC | 92,700 | $83,152 | 0.08% |
| GCM Grosvenor Holdings, LLC | 410,888 | $368,567 | 0.07% |